210 related articles for article (PubMed ID: 30356161)
1. Targeted killing of TNFR2-expressing tumor cells and T
Torrey H; Khodadoust M; Tran L; Baum D; Defusco A; Kim YH; Faustman DL
Leukemia; 2019 May; 33(5):1206-1218. PubMed ID: 30356161
[TBL] [Abstract][Full Text] [Related]
2. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
[TBL] [Abstract][Full Text] [Related]
3. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
4. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
5. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
7. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
9. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
Front Immunol; 2018; 9():1274. PubMed ID: 29922294
[TBL] [Abstract][Full Text] [Related]
10. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
11. A novel TNFR2 agonist antibody expands highly potent regulatory T cells.
Torrey H; Kühtreiber WM; Okubo Y; Tran L; Case K; Zheng H; Vanamee E; Faustman DL
Sci Signal; 2020 Dec; 13(661):. PubMed ID: 33293464
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
13. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
Chen X; Oppenheim JJ
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096506
[TBL] [Abstract][Full Text] [Related]
14. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
Hamano R; Huang J; Yoshimura T; Oppenheim JJ; Chen X
Eur J Immunol; 2011 Jul; 41(7):2010-20. PubMed ID: 21491419
[TBL] [Abstract][Full Text] [Related]
15. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
17. An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability
Urbano PCM; Koenen HJPM; Joosten I; He X
Front Immunol; 2018; 9():573. PubMed ID: 29619032
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
[TBL] [Abstract][Full Text] [Related]
19. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
20. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
